8-K Announcements
6Material company update
Apr 27, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Jan 12, 2026·SEC
Fulcrum Therapeutics, Inc.(FULC)Earnings, Financials & Key Ratios
FULC•NASDAQ
Price updated Jun 19, 2026
AboutFulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$83M-310.7%
- Net Income-$75M-670.0%
- EPS (Diluted)-1.18-637.5%
- ROE-25.3%-522.0%
FULC Key Insights
Fulcrum Therapeutics, Inc. (FULC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when FULC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
FULC Price & Volume
Fulcrum Therapeutics, Inc. (FULC) stock price & volume — 10-year historical chart
Loading chart...
FULC Growth Metrics
Fulcrum Therapeutics, Inc. (FULC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-14824.71%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1542.86%
Return on Capital
10 Years-209.46%
5 Years-37.9%
3 Years-28.58%
Last Year-28.12%
FULC Recent Earnings
Fulcrum Therapeutics, Inc. (FULC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 3/12 qtrs (75%)
Q2 2026Latest
Apr 27, 2026Metric
Actual
Est
EPS
$0.25+19.4%
$0.31
Rev
—
—
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.31+0.0%
$0.31
Rev
—
—
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$0.31-6.9%
$0.29
Rev
—
—
Q3 2025
Jul 29, 2025Metric
Actual
Est
EPS
$0.28+3.4%
$0.29
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 27, 2026 | $0.25vs $0.31+19.4% | — |
| Q1 2026 | Feb 24, 2026 | $0.31vs $0.31+0.0% | — |
| Q4 2025 | Oct 29, 2025 | $0.31vs $0.29-6.9% | — |
| Q3 2025 | Jul 29, 2025 | $0.28vs $0.29+3.4% | — |
Based on last 12 quarters of dataView full earnings history →
FULC Peer Comparison
Fulcrum Therapeutics, Inc. (FULC) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 |
Compare FULC vs Peers
Fulcrum Therapeutics, Inc. (FULC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
FULC Income Statement
Fulcrum Therapeutics, Inc. (FULC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 8.82M | 19.16M | 6.34M | 2.81M | 80M | 0 | 0 |
Revenue Growth % | - | - | - | - | 117.19% | -66.91% | -55.77% | 2752.05% | -100% | -100% |
Cost of Goods Sold | 715K | 1.34M | 2.05M | 59.04M | 69.7M | 76.78M | 0 | 63.39M | 1.39M | 0 |
COGS % of Revenue | - | - | - | 669.18% | 363.73% | 1210.69% | - | 79.23% | - | - |
Gross Profit | -715K▲ 0% | -1.34M▼ 88.1% | -2.05M▼ 52.6% | -50.22M▼ 2346.1% | -50.54M▼ 0.6% | -70.44M▼ 39.4% | 2.81M▲ 104.0% | 16.61M▲ 492.3% | -1.39M▼ 108.4% | 0▲ 0% |
Gross Margin % | - | - | - | -569.18% | -263.73% | -1110.69% | 100% | 20.77% | - | - |
Gross Profit Growth % | - | -88.11% | -52.64% | -2346.13% | -0.64% | -39.38% | 103.98% | 492.3% | -108.37% | - |
Operating Expenses | 22.99M | 33.5M | 56.57M | 21.39M | 30.52M | 42.12M | 113.47M | 38.51M | 83.38M | 86.55M |
OpEx % of Revenue | - | - | - | 242.46% | 159.24% | 664.16% | 4045.24% | 48.14% | - | - |
Selling, General & Admin | 4.5M | 8.31M | 13.14M | 21.39M | 30.52M | 41.69M | 41.67M | 36.45M | 28.67M | 29.77M |
SG&A % of Revenue | - | - | - | 242.46% | 159.24% | 657.43% | 1485.49% | 45.56% | - | - |
Research & Development | 18.49M | 25.18M | 43.43M | 59.04M | 69.7M | 76.78M | 71.8M | 63.39M | 56.1M | 56.78M |
R&D % of Revenue | - | - | - | 669.18% | 363.73% | 1210.69% | 2559.75% | 79.23% | - | - |
Other Operating Expenses | 28K | 392K | 0 | -59.04M | -69.7M | -76.36M | 0 | -61.32M | -1.39M | 0 |
Operating Income | -22.99M▲ 0% | -33.5M▼ 45.7% | -58.63M▼ 75.0% | -71.61M▼ 22.1% | -81.05M▼ 13.2% | -112.56M▼ 38.9% | -110.66M▲ 1.7% | -21.9M▲ 80.2% | -84.77M▼ 287.1% | -86.55M▲ 0% |
Operating Margin % | - | - | - | -811.64% | -422.97% | -1774.85% | -3945.24% | -27.37% | - | - |
Operating Income Growth % | - | -45.69% | -75.01% | -22.15% | -13.19% | -38.87% | 1.69% | 80.21% | -287.13% | - |
EBITDA | -22.28M | -32.15M | -56.57M | -69.23M | -78.54M | -110.15M | -108.49M | -20.3M | -83.38M | -85.52M |
EBITDA Margin % | - | - | - | -784.68% | -409.85% | -1736.79% | -3867.81% | -25.38% | - | - |
EBITDA Growth % | - | -44.33% | -75.95% | -22.38% | -13.44% | -40.24% | 1.5% | 81.29% | -310.65% | -677.48% |
D&A (Non-Cash Add-back) | 715K | 1.34M | 2.05M | 2.38M | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M | 1.04M |
EBIT | -22.99M | -33.5M | -82.68M | -71.61M | -81.05M | -112.13M | -110.66M | -19.83M | -74.88M | -57.23M |
Net Interest Income | 0 | 0 | 1.51M | 792K | 207K | 0 | 0 | 0 | 0 | 0 |
Interest Income | 0 | 0 | 1.51M | 792K | 207K | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 29K | 910K | -24.05M | 792K | 207K | 2.69M | 13.33M | 12.17M | 9.89M | 10.44M |
Pretax Income | -22.96M▲ 0% | -32.59M▼ 41.9% | -82.68M▼ 153.7% | -70.82M▲ 14.3% | -80.85M▼ 14.2% | -109.87M▼ 35.9% | -97.33M▲ 11.4% | -9.72M▲ 90.0% | -74.88M▼ 670.0% | -76.12M▲ 0% |
Pretax Margin % | - | - | - | -802.66% | -421.89% | -1732.43% | -3470.05% | -12.16% | - | - |
Income Tax | -1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -22.96M▲ 0% | -32.59M▼ 41.9% | -82.68M▼ 153.7% | -70.82M▲ 14.3% | -80.85M▼ 14.2% | -109.87M▼ 35.9% | -97.33M▲ 11.4% | -9.72M▲ 90.0% | -74.88M▼ 670.0% | -76.12M▲ 0% |
Net Margin % | - | - | - | -802.66% | -421.89% | -1732.43% | -3470.05% | -12.16% | - | - |
Net Income Growth % | - | -41.91% | -153.7% | 14.34% | -14.16% | -35.9% | 11.41% | 90.01% | -669.97% | -14824.71% |
Net Income (Continuing) | -22.96M | -32.59M | -82.68M | -70.82M | -80.85M | -109.87M | -97.33M | -9.72M | -74.88M | -76.12M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.36▲ 0% | -1.92▼ 41.2% | -3.49▼ 81.8% | -2.70▲ 22.6% | -2.22▲ 17.8% | -2.35▼ 5.9% | -1.59▲ 32.3% | -0.16▲ 89.9% | -1.18▼ 637.5% | -1.00▲ 0% |
EPS Growth % | - | -41.18% | -81.77% | 22.64% | 17.78% | -5.86% | 32.34% | 89.94% | -637.5% | -1542.86% |
EPS (Basic) | -1.36 | -1.92 | -3.49 | -2.70 | -2.22 | -2.35 | -1.59 | -0.16 | -1.18 | - |
Diluted Shares Outstanding | 16.94M | 16.94M | 22.66M | 25.35M | 35.36M | 44.99M | 61.31M | 61.98M | 63.35M | 76.22M |
Basic Shares Outstanding | 16.94M | 16.94M | 22.66M | 25.35M | 35.36M | 44.99M | 61.31M | 61.98M | 63.35M | 76.22M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
FULC Balance Sheet
Fulcrum Therapeutics, Inc. (FULC) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.34M | 74.09M | 100.08M | 112.91M | 226M | 207.52M | 242.2M | 249.92M | 357.48M | 338.67M |
Cash & Short-Term Investments | 407K | 72.8M | 96.71M | 112.91M | 218.16M | 202.92M | 236.22M | 241.02M | 352.31M | 333.32M |
Cash Only | 407K | 72.8M | 96.71M | 57.05M | 35.41M | 35.1M | 25.56M | 58.21M | 197.53M | 50.26M |
Short-Term Investments | 0 | 0 | 0 | 55.86M | 182.75M | 167.82M | 210.66M | 182.81M | 154.77M | 283.06M |
Accounts Receivable | 39K | 501K | 111K | 2.71M | 4.11M | 1.08M | 2.25M | 3.34M | 1.07M | 0 |
Days Sales Outstanding | - | - | - | 111.99 | 78.28 | 62.21 | 292.65 | 15.25 | - | - |
Inventory | 734K | 559K | 2.98M | -2.78M | -473K | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 374.7 | 151.7 | 528.92 | - | - | - | - | - | - | - |
Other Current Assets | 248K | 238K | 284K | 74K | 0 | 0 | 0 | 0 | 5.17M | 5.35M |
Total Non-Current Assets | 3M | 11.68M | 10.36M | 16.66M | 9M | 19.17M | 15.49M | 10.79M | 8.8M | 8.1M |
Property, Plant & Equipment | 2.94M | 10.55M | 87.94M | 8.4M | 7.37M | 15.97M | 12.39M | 9.58M | 7.07M | 6.35M |
Fixed Asset Turnover | - | - | - | 1.05x | 2.60x | 0.40x | 0.23x | 8.35x | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 1.09M | 1.09M | 1.09M | 1.09M | 1.09M | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 60K | 38K | -78.68M | 7.17M | 542K | 2.1M | 3.1M | 1.21M | 1.74M | 1.75M |
Total Assets | 4.34M▲ 0% | 85.77M▲ 1876.3% | 110.44M▲ 28.8% | 129.58M▲ 17.3% | 235M▲ 81.4% | 226.69M▼ 3.5% | 257.69M▲ 13.7% | 260.72M▲ 1.2% | 366.28M▲ 40.5% | 346.77M▲ 0% |
Asset Turnover | - | - | - | 0.07x | 0.08x | 0.03x | 0.01x | 0.31x | - | 0.00x |
Asset Growth % | - | 1876.29% | 28.76% | 17.33% | 81.36% | -3.54% | 13.68% | 1.17% | 40.49% | 38.18% |
Total Current Liabilities | 2.79M | 4.23M | 12.14M | 26.73M | 19.2M | 16.73M | 13.68M | 11.04M | 13.05M | 9.86M |
Accounts Payable | 1.67M | 1.26M | 2.19M | 4.08M | 4.79M | 3.64M | 2.76M | 1.16M | 1.59M | 2.45M |
Days Payables Outstanding | 854.05 | 342.75 | 388.65 | 25.22 | 25.07 | 17.29 | - | 6.7 | 418.04 | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 2.6M | 0 | 0 | 2.4M | 2.46M |
Deferred Revenue (Current) | 0 | 2.8M | 3.99M | 14.91M | 4.71M | 934K | 0 | 0 | 0 | 0 |
Other Current Liabilities | 20K | 781K | 3.68M | 4.79M | 4.71M | 5.34M | 396K | 463K | 9.05M | 4.95M |
Current Ratio | 0.48x | 17.52x | 8.24x | 4.23x | 11.77x | 12.41x | 17.71x | 22.63x | 27.40x | 34.33x |
Quick Ratio | 0.22x | 17.39x | 8.00x | 4.33x | 11.80x | 12.41x | 17.71x | 22.63x | 27.40x | 34.33x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 233K | 5.54M | 11.15M | 7.67M | 4.26M | 11.02M | 8.83M | 6.64M | 4.24M | 3.6M |
Long-Term Debt | 34.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.04M | 3.41M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 10.82M | 8.63M | 6.44M | 0 | 9.94M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | -34.35M | 5.54M | 5.13M | 4.7M | 4.26M | 0 | 197K | 197K | 197K | 197K |
Total Liabilities | 3.02M | 9.77M | 23.29M | 34.4M | 23.46M | 27.74M | 22.5M | 17.68M | 17.28M | 13.47M |
Total Debt | 34.59M | 46K | 50K | 17K | 0 | 13.42M | 10.82M | 8.63M | 6.44M | 5.87M |
Net Debt | 34.18M | -72.75M | -96.66M | -57.03M | -35.41M | -21.68M | -14.74M | -49.58M | -191.09M | -44.39M |
Debt / Equity | 26.16x | 0.00x | 0.00x | 0.00x | - | 0.07x | 0.05x | 0.04x | 0.02x | 0.02x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.07x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.52x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 1.32M▲ 0% | 76M▲ 5648.9% | 87.15M▲ 14.7% | 95.18M▲ 9.2% | 211.54M▲ 122.2% | 198.94M▼ 6.0% | 235.19M▲ 18.2% | 243.03M▲ 3.3% | 349M▲ 43.6% | 333.3M▲ 0% |
Equity Growth % | - | 5648.87% | 14.67% | 9.21% | 122.25% | -5.95% | 18.22% | 3.33% | 43.6% | 44.87% |
Book Value per Share | 0.08 | 4.49 | 3.85 | 3.75 | 5.98 | 4.42 | 3.84 | 3.92 | 5.51 | 4.37 |
Total Shareholders' Equity | 1.32M | 76M | 87.15M | 95.18M | 211.54M | 198.94M | 235.19M | 243.03M | 349M | 333.3M |
Common Stock | 1K | 16K | 23K | 28K | 41K | 52K | 62K | 54K | 67K | 67K |
Retained Earnings | -35.54M | -68.12M | -150.8M | -221.62M | -302.47M | -412.34M | -509.67M | -519.4M | -594.28M | -613.17M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -893K | -1.96M | -110.44M | -2K | -397K | -797K | -136K | 130K | 0 | -513K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FULC Cash Flow Statement
Fulcrum Therapeutics, Inc. (FULC) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -20.07M | -22.56M | -39.48M | -53.66M | -78.48M | -97.05M | -90.97M | -2.22M | -60.06M | -63.56M |
Operating CF Margin % | - | - | - | -608.13% | -409.53% | -1530.27% | -3242.96% | -2.77% | - | - |
Operating CF Growth % | - | -12.39% | -75% | -35.89% | -46.26% | -23.67% | 6.27% | 97.56% | -2608.07% | -120.98% |
Net Income | -22.96M | -32.59M | -82.68M | -70.82M | -80.85M | -109.87M | -97.33M | -9.72M | -74.88M | -76.12M |
Depreciation & Amortization | 715K | 1.34M | 2.05M | 2.38M | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M | 1.33M |
Stock-Based Compensation | 1.37M | 2.16M | 4.22M | 7.35M | 11.07M | 13.35M | 14.8M | 14.55M | 12.47M | 9.8M |
Deferred Taxes | 0 | 0 | 0 | 1.93M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.59M | 4.87M | 25.59M | -2M | 673K | 152K | -5.99M | -4.39M | -2.95M | -2.71M |
Working Capital Changes | 804K | 6.52M | 11.33M | 7.5M | -11.89M | -3.09M | -4.61M | -4.25M | 3.91M | 4.13M |
Change in Receivables | 0 | 0 | 0 | -2M | -500K | 2.5M | -308K | -1.56M | 2.1M | 979K |
Change in Inventory | 0 | 0 | 0 | 229K | 1.25M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 208K | -20K | 803K | 1.77M | 973K | -1.18M | -853K | -1.59M | 428K | 943K |
Cash from Investing | -1.91M | -8.98M | -944K | -57.14M | -129.67M | 12.41M | -36.69M | 32.23M | 30.72M | -96.71M |
Capital Expenditures | -1.91M | -8.98M | -853K | -1.34M | -1.71M | -1.96M | -508K | -278K | -314K | -322K |
CapEx % of Revenue | - | - | - | 15.21% | 8.94% | 30.95% | 18.11% | 0.35% | - | - |
Acquisitions | 0 | 0 | 0 | 55.8M | 127.96M | -14.38M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | -91K | -55.8M | -127.96M | 14.38M | 0 | 0 | 0 | 0 |
Cash from Financing | 17.66M | 105.03M | 64.34M | 71.13M | 186.51M | 84.32M | 118.12M | 2.75M | 168.67M | 168.35M |
Debt Issued (Net) | 0 | -70K | -45K | -50K | -18K | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 105.08M | 64.14M | 69.95M | 182.86M | 80.8M | 117.34M | 2.75M | 168.67M | 168.67M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 17.66M | 12K | 249K | 1.24M | 3.67M | 3.52M | 777K | 0 | 0 | -312K |
Net Change in Cash | -4.32M▲ 0% | 73.48M▲ 1801.0% | 23.92M▼ 67.5% | -39.66M▼ 265.8% | -21.64M▲ 45.4% | -314K▲ 98.5% | -9.54M▼ 2936.6% | 32.76M▲ 443.6% | 139.32M▲ 325.3% | 8.09M▲ 0% |
Free Cash Flow | -21.98M▲ 0% | -31.54M▼ 43.5% | -40.34M▼ 27.9% | -55M▼ 36.3% | -80.19M▼ 45.8% | -99.01M▼ 23.5% | -91.47M▲ 7.6% | -2.5M▲ 97.3% | -60.38M▼ 2319.0% | -63.88M▲ 0% |
FCF Margin % | - | - | - | -623.34% | -418.47% | -1561.23% | -3261.07% | -3.12% | - | - |
FCF Growth % | - | -43.49% | -27.88% | -36.35% | -45.81% | -23.47% | 7.62% | 97.27% | -2319.03% | -945.09% |
FCF per Share | -1.30 | -1.86 | -1.78 | -2.17 | -2.27 | -2.20 | -1.49 | -0.04 | -0.95 | -0.84 |
FCF Conversion (FCF/Net Income) | 0.87x | 0.69x | 0.48x | 0.76x | 0.97x | 0.88x | 0.93x | 0.23x | 0.80x | 0.84x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
FULC Key Ratios
Fulcrum Therapeutics, Inc. (FULC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -84.29% | -101.35% | -77.68% | -52.72% | -53.53% | -44.84% | -4.07% | -25.3% | -27.8% |
Return on Invested Capital (ROIC) | -129.67% | - | -375.11% | -56.74% | -47.78% | -41.74% | -7.94% | -36.19% | -33.1% |
Gross Margin | - | - | -569.18% | -263.73% | -1110.69% | 100% | 20.77% | - | - |
Net Margin | - | - | -802.66% | -421.89% | -1732.43% | -3470.05% | -12.16% | - | - |
Debt / Equity | 0.00x | 0.00x | 0.00x | - | 0.07x | 0.05x | 0.04x | 0.02x | 0.02x |
FCF Conversion | 0.69x | 0.48x | 0.76x | 0.97x | 0.88x | 0.93x | 0.23x | 0.80x | 0.84x |
Revenue Growth | - | - | - | 117.19% | -66.91% | -55.77% | 2752.05% | -100% | -100% |
Related:FULC Dividend History·FULC Revenue History·FULC Price History·FULC P/E History·FULC Financial Ratios·FULC Institutional Holders
FULC SEC Filings & Documents
Fulcrum Therapeutics, Inc. (FULC) SEC filings — annual & quarterly reports (10-K, 10-Q)
FULC Frequently Asked Questions
Fulcrum Therapeutics, Inc. (FULC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Fulcrum Therapeutics, Inc. (FULC) saw revenue decline by 100.0% over the past year.
Fulcrum Therapeutics, Inc. (FULC) reported a net loss of $76.1M for fiscal year 2025.
Dividend & Returns
Fulcrum Therapeutics, Inc. (FULC) has a return on equity (ROE) of -25.3%. Negative ROE indicates the company is unprofitable.
Fulcrum Therapeutics, Inc. (FULC) had negative free cash flow of $63.9M in fiscal year 2025, likely due to heavy capital investments.